Imagine needing a drug and the company that has exclusive rights to it has just drastically increased the price. Philadelphila’s URL Pharma has been accused of price-gouging its gout treatment after the price of Colcrys went from 10 cents to $5 per pill.
Health & Science reporter Carolyn Beeler spoke with a past president of the American College of Rheumatology who says an FDA rule is to blame for the price increase.
Once URL Pharma passed the drug through new clinical trials in 2009, it won exclusive rights to Colcrys, eliminating competition and then raising the price. Read about the company’s take on the price increase and what critics have to say.